Editor LSA

Stocks in Queue: Immunomedics, Inc. (NASDAQ:IMMU), KiOR Inc (NASDAQ:KIOR), PDL BioPharma Inc. (NASDAQ:PDLI), Opexa Therapeutics Inc (NASDAQ:OPXA)

 

Lewes, DE -- (SBWIRE) -- 09/07/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Immunomedics, Inc. (NASDAQ:IMMU), KiOR Inc (NASDAQ:KIOR), PDL BioPharma Inc. (NASDAQ:PDLI), Opexa Therapeutics Inc (NASDAQ:OPXA).

Immunomedics, Inc. (NASDAQ:IMMU) decreased -1.58% and closed at $6.21 on a traded volume of 1.30 million shares, in comparison to 1.01 million shares of average trading volume. So far this year, the stock is down over -1.58%.

The company has a total market capitalization of $515.03 million and its total outstanding shares are 82.94 million.

Will IMMU Get Buyers Even After The Recent Rally? Find Out Here

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases.

KiOR Inc (NASDAQ:KIOR) plunged -13.37% and closed at $1.49 on a traded volume of 1.26 million shares, whereas its average trading volume is 616.766 shares. In the last three months, the stock is down -64.69%. The Intra-day range for the stock is $1.43 and $1.67.

Will KIOR Get Buyers Even After The Recent Rally? Find Out Here

KiOR, Inc., a renewable fuels company, engages in the production and sale of cellulosic gasoline and diesel from non-food biomass using its proprietary biomass-to-cellulosic fuel technology platform.

PDL BioPharma Inc. (NASDAQ:PDLI) dropped -0.89% and closed at $7.76. So far in three months, the stock is down -1.52%. The 52-week range for the stock is $6.50 and $8.48 and during the previous trading session the stock touched its highest price at $7.86. Its introductory price for the day was $7.86, with the overall traded volume of 1.25 million shares.

Will PDLI Get Buyers Even After The Recent Rally? Find Out Here

PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities.

Opexa Therapeutics Inc (NASDAQ:OPXA) after opening its trade at the price of $1.53, jumped 1.32% to close at $1.53 for the day. The stock moved on a traded volume of 1.25 million shares, in comparison to 2.45 million shares of average trading volume.

The 52-week range for the stock is $1.07 and $5.19 and during the previous trading session the stock touched its highest price at $1.54.

Will OPXA Continue To Move Higher? Find Out Here

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology.

About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/